Annual Drug Patent Expirations for LIVALO Livalo is a drug marketed by Kowa Co and is included in one NDA. […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European […]
Source
Which pharmaceutical companies have the most SPCs in Spain? Read Post »
Annual Drug Patent Expirations for ADASUVE Adasuve is a drug marketed by Alexza Pharms and is included in one NDA. […]
Source
New patent expiration for Alexza Pharms drug ADASUVE Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most patents in Netherlands. Patents must be filed in each country (or, […]
Source
Which pharmaceutical companies have the most drug patents in Netherlands? Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the pharmaceutical companies with the most patents in Portugal. Patents must be filed in each country (or, […]
Source
Which pharmaceutical companies have the most drug patents in Portugal? Read Post »
Annual Drug Patent Expirations for PREZCOBIX Prezcobix is a drug marketed by Janssen Prods and is included in one NDA. […]
Source
New patent expiration for Janssen Prods drug PREZCOBIX Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »